Modelling the potential clinical and economic impact of universal immunisation with nirsevimab versus standard of practice for protecting all neonates and infants in their first respiratory syncytial virus season in Spain.

Autor: Gil-Prieto R; Department of Medical Specialties and Public Health, Rey Juan Carlos University, Madrid, Spain., Pérez JJ; Public Health Directorate, Murcia Region, Spain., Drago G; Market Access, Sanofi, Barcelona, Spain., Kieffer A; Global Health Economics and Value Assessment, Sanofi, Lyon, France., Roïz J; Evidera, London, UK., Kazmierska P; Evidera, London, UK., Sardesai A; Evidera, San Francisco, CA, USA., de Boisvilliers S; Evidera, Ivry-sur-Seine, France., López-Belmonte JL; Market Access, Sanofi, Calle Martínez Villergas, 52, Madrid, 28027, Spain. juanluis.lopez-belmonte@sanofi.com., Beuvelet M; Global Health Economics and Value Assessment, Sanofi, Lyon, France., Aldean JA; Paediatric Department, Hospital Costa del Sol, Marbella, Spain.
Jazyk: angličtina
Zdroj: BMC infectious diseases [BMC Infect Dis] 2024 Sep 06; Vol. 24 (1), pp. 924. Date of Electronic Publication: 2024 Sep 06.
DOI: 10.1186/s12879-024-09642-0
Abstrakt: Background: Respiratory syncytial virus (RSV) is associated with substantial morbidity among infants. This study modelled the potential public health and economic impact of nirsevimab, a long-acting monoclonal antibody, as an immunoprophylactic strategy for all infants in Spain in their first RSV season.
Methods: A static decision-analytic model of the Spanish birth cohort during its first RSV season was developed to estimate the impact of nirsevimab on RSV-related health events and costs versus the standard of practice (SoP). Spain-specific costs and epidemiological data were used as model inputs. Modelled outcomes included RSV-related outpatient visits, emerging room (ER) visits, hospitalisations - including pediatric intensive care unit (PICU) admission, mechanical ventilation, and inpatient mortality.
Results: Under the current SoP, RSV caused 151,741 primary care visits, 38,798 ER visits, 12,889 hospitalisations, 1,412 PICU admissions, and 16 deaths over a single season, representing a cost of €71.8 million from a healthcare payer perspective. Universal immunisation of all infants with nirsevimab was expected to prevent 97,157 primary care visits (64.0% reduction), 24,789 ER visits (63.9%), 8,185 hospitalisations (63.5%), 869 PICU admissions (61.5%), and 9 inpatient deaths (52.6%), saving €47.8 million (62.4%) in healthcare costs.
Conclusions: These results suggest that immunisation with nirsevimab of all infants experiencing their first RSV season in Spain is likely to prevent thousands of RSV-related health events and save considerable costs versus the current SoP.
(© 2024. The Author(s).)
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje